FuelCell Energy Inc vs Sana Biotechnology Inc — how do they compare? FuelCell Energy Inc trades at $20.85 (market cap $1.54B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: FuelCell Energy Inc is the larger of the two by market cap, and FuelCell Energy Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| FCEL | SANA | |
|---|---|---|
Market Cap | $1.54B | $1.13B |
Sector | Industrials | Health |
52-Week High | $36.01 | $5.92 |
52-Week Low | $3.92 | $2.68 |
Enterprise Value | $1.38B | $1.05B |
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $19.83, down 2.94% on the day, with a bearish technical signal and negative profitability metrics. The company reported a net loss of $187.90 million on $158.16 million revenue for 2025, though it beat EPS estimates in two recent quarters. Recent news highlights partnerships with Siemens and AI-driven power demand opportunities, contributing to volatile stock performance.
Outlook remains speculative with high risk due to persistent losses and negative margins, offset by analyst optimism (45% buy rating) and a $20.75 consensus price target. Key risks include cash burn, competitive pressures, and execution challenges in scaling hydrogen technology.
SANA Biotechnology trades at $3.775, up 4.57% with strong technical momentum as moving averages signal bullish sentiment. The company shows significant financial challenges with negative ROE (-152.87%) and net income (-$244.17M in 2025), though recent analyst upgrades and clinical developments in cell therapy research provide optimism. Cash flow remains negative but improved from -$55M to -$14M year-over-year, while the stock benefits from 82% buy ratings from analysts.
Investment outlook balances high-risk fundamentals against promising biotechnology breakthroughs. The primary opportunity lies in successful clinical trial outcomes and market adoption of engineered cell therapies, while risks include sustained cash burn, execution challenges, and competitive pressures in the genomics space. Wall Street's $9.50 price target suggests substantial upside potential if operational improvements materialize.
Trailing returns across standard periods
Latest headlines on both assets
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →